SCHEMBL26684590

SCHEMBL26684590

COc1cc(CO)cc(OC)c1C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 6/20 0.46
▸ CNR1 P21554 5/20 0.46
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HTR2A P28223 2/20 0.42
▸ ABCB1 P08183 1/20 0.41
▸ CHRM2 P08172 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ CHRM5 P08912 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA4 P22748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26684636 0.98 CNR2 (0.45) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL26684938 0.86 CNR2 (0.43) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL26684865 0.84 HTR2A (0.43) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL30038814 0.82 HTR2A (0.44) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL30668190 0.80 CNR2 (0.41) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL24028163 0.79 PTGDR2 (0.49) ALDH1A1HTR2APTGDR2POLBRECQL
SCHEMBL19943971 0.78 ABCB1 (0.45) CNR2CNR1KDM4EABCB1PTGDR2
SCHEMBL5358992 0.78 ABCB1 (0.45) CNR2CNR1HTR2AABCB1CHRM1
SCHEMBL30668194 0.78 PGK1 (0.42) CNR2CNR1ALDH1A1KDM4EHTR2A
SCHEMBL28848582 0.77 TNKS2 (0.45) CNR2CNR1HTR2AABCB1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382250-A1 STILBENE DERIVATIVE AS AHR AGONIST AND USE THEREOF NANJING GRITPHARMACO LTD (CN) 2025-12-18 — — US disclosed
EP-4524123-A1 STILBENE DERIVATIVE AS AHR AGONIST AND USE THEREOF Nanjing Gritpharmaco., Ltd. (CN) 2025-03-19 — — EP disclosed
WO-2023217049-A1 STILBENE DERIVATIVE AS AHR AGONIST AND USE THEREOF 南京济群医药科技股份有限公司 2023-11-16 — — WO disclosed
CN-117003620-A Stilbene derivatives as AhR agonists and uses thereof 南京济群医药科技股份有限公司 2023-11-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382250-A1 STILBENE DERIVATIVE AS AHR AGONIST AND USE THEREOF AHR, ARNT, RORB CNR2 277/4885CNR1 284/4885ALDH1A1 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback